John T Randolph

List of Publications by Year
in descending order

9 papers	322 citations	1478505 6 h-index	1474206 9 g-index
9 all docs	9 docs citations	9 times ranked	537 citing authors

#	Article	IF	Citations
1	Discovery of ABT-267, a Pan-Genotypic Inhibitor of HCV NS5A. Journal of Medicinal Chemistry, 2014, 57, 2047-2057.	6.4	120
2	In Vitro Antiviral Activity and Resistance Profile of the Next-Generation Hepatitis C Virus NS5A Inhibitor Pibrentasvir. Antimicrobial Agents and Chemotherapy, 2017, 61, .	3.2	117
3	Highlights of the Structureâ€“Activity Relationships of Benzimidazole Linked Pyrrolidines Leading to the Discovery of the Hepatitis C Virus NS5A Inhibitor Pibrentasvir (ABT-530). Journal of Medicinal Chemistry, 2018, 61, 4052-4066.	6.4	42
4	Synthesis and Biological Characterization of Aryl Uracil Inhibitors of Hepatitis C Virus NS5B Polymerase: Discovery of ABT-072, a trans-Stilbene Analog with Good Oral Bioavailability. Journal of Medicinal Chemistry, 2018, 61, 1153-1163.	6.4	17
5	Prodrug Strategies to Improve the Solubility of the HCV NS5A Inhibitor Pibrentasvir (ABT-530). Journal of Medicinal Chemistry, 2020, 63, 11034-11044.	6.4	9
6	High potency improvements to weak aryl uracil HCV polymerase inhibitor leads. Bioorganic and Medicinal Chemistry Letters, 2013, 23, 4367-4369.	2.2	6
7	Discovery of fluorobenzimidazole HCV NS5A inhibitors. Bioorganic and Medicinal Chemistry Letters, 2016, 26, 5462-5467.	2.2	5
8	Desymmetrization of pibrentasvir for efficient prodrug synthesis. Chemical Science, 2021, 12, 10076-10082.	7.4	5
9	HCV NS5A as an Antiviral Therapeutic Target: From Validation to the Discovery and Development of Ombitasvir and Pibrentasvir as Components of IFN-Sparing HCV Curative Treatments. Topics in Medicinal Chemistry, 2019, , 133-156.	0.8	1